Skip to Main ContentSkip to FooterSkip to Search
  1. Home
  2.  » 
  3. Biologics
  4.  » 
  5. Drug Substance
  6.  » 
  7. Bioconjugate Development
  8.  » Specialized Linkers

Antibody-drug Conjugates & Bioconjugates


scientistData generated from SMARTag-designed ADCs to date demonstrate conjugate stability – even with cleavable linkers – to deliver efficacy with improved tolerability and a wider therapeutic window.


RED-106, a proprietary noncleavable linker with a maytansine payload, is used in a Phase 1 clinical trial (TRPH-222) offering:

  • Stable payload attachment to mAb
  • No bystander effect, reducing off-target toxicities
  • Maintains potency in cells with upregulated P-glycoprotein
  • Can induce immunogenic cell death in target cells
  • Improved tolerability and efficacy as compared to conventional maytansine linkers (e.g., Kadcyla®)

noncleavable linkers


Traditional cleavable linkers require one “key” for payload release and can lead to release during circulation, while SMARTag® tandem-cleavage linkers require two “keys” for payload release where tumor cells have both keys. This offers superior stability and reduced toxicity in vivo.